

Financial news for NKTR dated on 2020-06-04: Nektar Therapeutics Highlights Data From Phase 1b Study Of NKTR-358 At European Congress Of Rheumatology

Financial news for NKTR dated on 2020-05-22: Nektar Therapeutics Highlights Publication Of Results From Phase 1 Dose-Escalation Study For Bempegaldesleukin Plus Nivolumab In 'Cancer Discovery' Journal

Financial news for NKTR dated on 2020-05-18: Oppenheimer Maintains Perform on Nektar Therapeutics, Raises Price Target to \$25

Financial news for NKTR dated on 2020-05-12: HC Wainwright & Co. Reiterates Neutral on Nektar Therapeutics, Lowers Price Target to \$26

Financial news for NKTR dated on 2020-05-08: SVB Leerink Maintains Market Perform on Nektar Therapeutics, Raises Price Target to \$18

Financial news for NKTR dated on 2020-05-08: Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for NKTR dated on 2020-05-07: Nektar Therapeutics Q1 EPS \$(0.530) Beats \$(0.710) Estimate, Sales \$50.573M Beat \$47.640M Estimate

Financial news for NKTR dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for NKTR dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for NKTR dated on 2020-04-22: Benchmark Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target to \$26

Financial news for NKTR dated on 2020-04-17: Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.

Financial news for NKTR dated on 2020-03-30: Nektar Therapeutics shares are trading higher after Goldman Sachs upgraded the company's stock from Sell to Neutral and raised its price target from \$18 to \$20.

Financial news for NKTR dated on 2020-03-30: Benzinga's Top Upgrades, Downgrades For March 30, 2020

Financial news for NKTR dated on 2020-03-30: Goldman Sachs Upgrades Nektar Therapeutics to Neutral, Raises Price Target to \$20

Financial news for NKTR dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for NKTR dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for NKTR dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for NKTR dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for NKTR dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for NKTR dated on 2020-03-10: Shares of several healthcare companies are trading higher as markets rebound following Monday's selloff. US President Trump on Monday indicated the US may implement payroll tax cuts and other measures to support the economy amid the coronavirus outbreak.

Financial news for NKTR dated on 2020-03-09: JP Morgan Maintains Neutral on Nektar Therapeutics, Lowers Price Target to \$27

Financial news for NKTR dated on 2020-03-04: Benzinga's Top Upgrades, Downgrades For March 4, 2020

Financial news for NKTR dated on 2020-03-04: Barclays Initiates Coverage On Nektar Therapeutics with Overweight Rating, Announces \$30 Price Target

Financial news for NKTR dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for NKTR dated on 2020-02-27: Nektar Therapeutics Q4 EPS \$(0.64) Beats \$(0.68) Estimate, Sales \$33.9M Beat \$26.93M Estimate

Financial news for NKTR dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for NKTR dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for NKTR dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for NKTR dated on 2020-02-12: Shares of several healthcare companies are trading higher in sympathy with the overall market after China reported the lowest number of new coronavirus cases since late January.

Financial news for NKTR dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for NKTR dated on 2020-02-04: 85 Biggest Movers From Yesterday

Financial news for NKTR dated on 2020-02-03: 61 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2020-02-03: Benzinga's Top Upgrades, Downgrades For February 3, 2020

Financial news for NKTR dated on 2020-02-03: Nektar Therapeutics shares are trading higher after Mizuho upgraded the stock from Neutral to Buy and raised the price target from \$21 to \$35 per share.

Financial news for NKTR dated on 2020-02-03: Mizuho Upgrades Nektar Therapeutics to Buy, Raises Price Target to \$35

Financial news for NKTR dated on 2020-01-27: Nektar Therapeutics shares are trading lower in sympathy with the overall market as concerns about the Wuhan coronavirus continue to grow, prompting travel bans in multiple Chinese cities.

Financial news for NKTR dated on 2020-01-22: 26 Biotechnology Stocks Moving In Wednesday's After-Market Session

Financial news for NKTR dated on 2020-01-22: 36 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for NKTR dated on 2020-01-16: 75 Biggest Movers From Yesterday

Financial news for NKTR dated on 2020-01-15: Mid-Afternoon Market Update: OrganiGram Rises Following Q1 Results; Nektar Therapeutics Shares Plummet

Financial news for NKTR dated on 2020-01-15: Mid-Day Market Update: Concrete Pumping Falls On Weak Q4 Results; Fluent Shares Jump

Financial news for NKTR dated on 2020-01-15: 36 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NKTR dated on 2020-01-15: Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 15, 2020: GS, RSX, NKTR, NVAX, ACB

Financial news for NKTR dated on 2020-01-15: Nektar Slumps As FDA Panel Gives Thumbs Down To Opioid Pain Drug; Program Shelved

Financial news for NKTR dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for NKTR dated on 2020-01-15: 34 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for NKTR dated on 2020-01-15: 21 Stocks Moving in Wednesday's Pre-Market Session

Financial news for NKTR dated on 2020-01-15: Nektar Therapeutics shares are trading lower after the FDA AdCom panel voted unanimously against approval of the company's Oxycodol painkiller.

Financial news for NKTR dated on 2020-01-14: Hearing FDA AdCom Panel Has Unanimously Voted Against Approval Of Nektar's Opioid Painkiller

Financial news for NKTR dated on 2020-01-14: Nektar Therapeutics shares are trading lower as the FDA's AdCom panel meeting on the company's Oxycodol is underway. Unconfirmed rumors suggest data obtained from a study is not substantial enough to support proposed use.

Financial news for NKTR dated on 2020-01-14: Hearing Nektar After-Hours Downside Attributed To Comments From AdCom Panel On Oxycodol Suggested Data Obtained From 1 Study Not Substantial Enough To Support Proposed Use

Financial news for NKTR dated on 2020-01-14: Nektar Therapeutics Shares Down 20% On Heavy After-Hours Volume; FDA AdCom Panel Meeting On Co.'s Oxycodol Currently Underway

Financial news for NKTR dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for NKTR dated on 2020-01-13: 55 Biggest Movers From Friday

Financial news for NKTR dated on 2020-01-12: The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO

Financial news for NKTR dated on 2020-01-10: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for NKTR dated on 2020-01-10: Nektar Therapeutics shares are trading higher after the company and Bristol-Myers agreed to a new joint development plan to advance bempeg plus nivolumab into multiple new registrational trials.

Financial news for NKTR dated on 2020-01-10: UPDATE: Nektar, Bristol Amendment Includes ' new joint development plan under which Nektar and Bristol-Myers Squibb will expand the active clinical development program for bempeg plus nivolumab from three ongoing registrational trials'

Financial news for NKTR dated on 2020-01-10: Nektar Therapeutics, Bristol-Myers Amend Strategic Collaboration For Bempegaldesleukin Plus Opdivo

Financial news for NKTR dated on 2020-01-09: 20 Stocks Moving in Thursday's Pre-Market Session

Financial news for NKTR dated on 2020-01-01: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for NKTR dated on 2019-12-19: 10 Stocks That Could Be Tax-Loss Buying Opportunities

Financial news for NKTR dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-12-09: Nektar Therapeutics shares are trading higher potentially after the company presented positive data for Abstract 2866 on Sunday, and in anticipation of the company presenting new preclinical data today at the ASH 2019 meeting.

Financial news for NKTR dated on 2019-12-09: Nektar Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for NKTR dated on 2019-12-06: Nektar Therapeutics shares are trading higher in sympathy with the overall market amid a rally in US equities following strong November jobs data.

Financial news for NKTR dated on 2019-11-20: Nektar Therapeutics shares are trading higher as the company presents at the Jefferies 2019 London Healthcare Conference.

Financial news for NKTR dated on 2019-11-19: 72 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-11-18: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2019-11-18: Nektar Therapeutics shares are trading lower. Not seeing any news to justify the price action.

Financial news for NKTR dated on 2019-11-13: JP Morgan Maintains Neutral on Nektar

Therapeutics, Lowers Price Target to \$28

Financial news for NKTR dated on 2019-11-12: Canaccord Genuity Maintains Buy on Nektar Therapeutics, Raises Price Target to \$24

Financial news for NKTR dated on 2019-11-11: UPDATE: H.C. Wainwright On Nektar Therapeutics Notes 'reasons to be cautious on this dataset include:'

Financial news for NKTR dated on 2019-11-11: UPDATE: H.C. Wainwright Maintains Neutral On Nektar Therapeutics, Raises Target To \$32 As Firm Notes 'Upward Bias Exiting SITC'; 'Durability in frontline melanoma is reassuring, but we remain wary'

Financial news for NKTR dated on 2019-11-11: H.C. Wainwright Earlier Maintained Neutral on Nektar Therapeutics, Raised Price Target to \$32

Financial news for NKTR dated on 2019-11-11: Nektar Therapeutics shares are trading higher after the company presented data from its first-in-human phase 1 trial of its NKTR-358 Novel T regulatory cell stimulator.

Financial news for NKTR dated on 2019-11-11: 20 Stocks Moving in Monday's Pre-Market Session

Financial news for NKTR dated on 2019-11-10: Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at ACR 2019

Financial news for NKTR dated on 2019-11-08: Nektar Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for NKTR dated on 2019-11-08: These Are The Stocks Being Traded By Some Of The Top Traders On Webull

Financial news for NKTR dated on 2019-11-07: UPDATE: Piper Jaffray On Nektar Also Notes 'We look forward to the melanoma/PIVOT-02 cohort update at SITC this weekend and are encouraged to see more of the pipeline advance into clinical development (255/IL-15 and 358/T-reg)'

Financial news for NKTR dated on 2019-11-07: UPDATE: Piper Jaffray Maintains Overweight On Nektar, Lowers Tgt To \$35 After Co. 'updated the timelines for topline readouts', Which Are Delayed Approx, 1 Year, 'For 3 of 6 planned registrational trials (1L melanoma, 1L bladder, and 1L RCC)' With BMJ

Financial news for NKTR dated on 2019-11-07: Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for NKTR dated on 2019-11-07: 10 Biggest Price Target Changes For Thursday

Financial news for NKTR dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for NKTR dated on 2019-11-07: Piper Jaffray Maintains Overweight on Nektar Therapeutics, Lowers Price Target to \$35

Financial news for NKTR dated on 2019-11-06: Nektar Therapeutics Q3 EPS \$(0.56) Beats \$(0.73) Estimate, Sales \$29.218M Beat \$26.4M Estimate

Financial news for NKTR dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for NKTR dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for NKTR dated on 2019-11-01: Nektar Therapeutics shares are trading higher on seemingly no company-specific news.

Financial news for NKTR dated on 2019-10-28: Nektar Therapeutics shares are trading higher in sympathy with the overall market from progression in U.S.-China trade talks and positive sentiment from strong earnings reports.

Financial news for NKTR dated on 2019-10-24: Oppenheimer Initiates Coverage On Nektar Therapeutics with Perform Rating, Announces \$18 Price Target

Financial news for NKTR dated on 2019-10-23: 16 Stocks With The Highest Long-Term Sales Growth Rate

Financial news for NKTR dated on 2019-10-22: 15 Stocks Projected To Have The Biggest 5-Year EPS Declines

Financial news for NKTR dated on 2019-10-16: Nektar Therapeutics Initiates First-In-Human Phase 1 Clinical Study Of NKTR-255, An IL-15 Agonist, In Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma Or Multiple Myeloma

Financial news for NKTR dated on 2019-10-16: 63 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-10-15: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NKTR dated on 2019-10-15: Stocks That Hit 52-Week Lows On Tuesday

Financial news for NKTR dated on 2019-10-15: Nektar Therapeutics shares are trading higher with the overall market. Not seeing any news to justify price action.

Financial news for NKTR dated on 2019-10-15: The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

Financial news for NKTR dated on 2019-10-14: Nektar Therapeutics shares are trading lower despite no company-specific news. The stock broke below the \$16.25 support level and continued to trade lower.

Financial news for NKTR dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for NKTR dated on 2019-10-10: Stocks That Hit 52-Week Lows On Thursday

Financial news for NKTR dated on 2019-10-09: Stocks That Hit 52-Week Lows On Wednesday

Financial news for NKTR dated on 2019-10-09: The Daily Biotech Pulse: FDA Approves Clinuvcl Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug

Financial news for NKTR dated on 2019-10-09: 42 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-10-08: Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence'

Financial news for NKTR dated on 2019-10-08: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NKTR dated on 2019-10-08: UPDATE: Goldman Downgrades Nektar Therapeutics To Sell, Lowers Target To \$16 As Believes 'near-term catalysts are unlikely to re-rate the stock in the face of quality issues and a narrower focus for bempegaldesleukin'

Financial news for NKTR dated on 2019-10-08: Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on \$250 billion worth of goods from 25% to 30% on Oct 15.

Financial news for NKTR dated on 2019-10-08: Benzinga's Top Upgrades, Downgrades For October 8, 2019

Financial news for NKTR dated on 2019-10-08: 10 Biggest Price Target Changes For Tuesday

Financial news for NKTR dated on 2019-10-08: 9 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for NKTR dated on 2019-10-08: 21 Stocks Moving in Tuesday's Pre-Market Session

Financial news for NKTR dated on 2019-10-08: Nektar Therapeutics shares are trading lower after Goldman Sachs downgraded the company's stock from Buy to Sell and lowered the price target from \$54 to \$16.

Financial news for NKTR dated on 2019-10-08: Goldman Sachs Downgrades Nektar Therapeutics to Sell, Lowers Price Target to \$16

Financial news for NKTR dated on 2019-10-07: Nektar Therapeutics Announces Initiation Of Two Clinical Studies Of Novel T Regulatory Cell Stimulator NKTR-358 In Patients With Psoriasis And Atopic Dermatitis

Financial news for NKTR dated on 2019-10-02: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a

recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.

Financial news for NKTR dated on 2019-09-26: Las Vegas Sands Set To Join S&P 500; Nektar Therapeutics To Join S&P Midcap 400

Financial news for NKTR dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for NKTR dated on 2019-09-26: Nektar Therapeutics shares are trading lower after the company presented data from its PIVOT-02 study of bempegaldesleukin in triple-negative breast cancer patients

Financial news for NKTR dated on 2019-09-26: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

Financial news for NKTR dated on 2019-09-26: Nektar Therapeutics Highlights Presentation Of Data From PIVOT-02 Study Of NKTR-214 With Nivolumab In Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Financial news for NKTR dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for NKTR dated on 2019-09-23: Nektar Therapeutics Announces Abstract Accepted For Presentation At The 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference

Financial news for NKTR dated on 2019-09-16: Nektar Therapeutics shares trading higher for the fifth out of six days following news on Tuesday of last week the company's Chief Scientific Officer purchased 15,000 shares. The stock held above a \$20 technical level today.

Financial news for NKTR dated on 2019-09-11: Nektar Therapeutics Shares Spike Above \$20 Resistance Level, Now Up 2% For Session

Financial news for NKTR dated on 2019-09-11: 80 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-09-10: Nektar Therapeutics shares are trading higher in sympathy with the strength of the biotechnology sector. The company's Chief Scientific Officer, Stephen Doberstein, also bought 15,000 shares of the company's stock.

Financial news for NKTR dated on 2019-09-10: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NKTR dated on 2019-08-29: The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

Financial news for NKTR dated on 2019-08-25: The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend

Financial news for NKTR dated on 2019-08-21: Stocks That Hit 52-Week Lows On Wednesday

Financial news for NKTR dated on 2019-08-21: The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform

Financial news for NKTR dated on 2019-08-13: 76 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-08-12: Shares of several healthcare companies are trading lower in sympathy with the overall market as the Treasury yield continues to decline along with ongoing trade tensions with China.

Financial news for NKTR dated on 2019-08-12: 54 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2019-08-12: 90 Biggest Movers From Friday

Financial news for NKTR dated on 2019-08-09: 75 Stocks Moving In Friday's Mid-Day Session

Financial news for NKTR dated on 2019-08-09: Large Option Trader Buying Nektar Calls Following Stock Crash

Financial news for NKTR dated on 2019-08-09: A Look At Benzinga Pro's Most-Searched Tickers For August 9, 2019

Financial news for NKTR dated on 2019-08-09: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday., August 09, 2019

Financial news for NKTR dated on 2019-08-09: Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer Drug

Financial news for NKTR dated on 2019-08-09: Benzinga's Top Upgrades, Downgrades For August 9, 2019

Financial news for NKTR dated on 2019-08-09: What Caused The Opening Gap In Nektar?

Financial news for NKTR dated on 2019-08-09: BMO Capital Maintains Outperform on Nektar Therapeutics, Lowers Price Target to \$41

Financial news for NKTR dated on 2019-08-09: 31 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for NKTR dated on 2019-08-09: 10 Biggest Price Target Changes For Friday

Financial news for NKTR dated on 2019-08-09: 52 Stocks Moving In Friday's Pre-Market Session

Financial news for NKTR dated on 2019-08-09: Mizuho Downgrades Nektar Therapeutics to Neutral, Lowers Price Target to \$21

Financial news for NKTR dated on 2019-08-09: Jefferies Downgrades Nektar Therapeutics to Hold

Financial news for NKTR dated on 2019-08-09: Nektar Therapeutics shares are trading lower after the company reported worse-than-expected Q2 sales results. JP Morgan also downgraded the company's stock from Overweight to Neutral.

Financial news for NKTR dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for NKTR dated on 2019-08-09: JP Morgan Downgrades Nektar Therapeutics to Neutral

Financial news for NKTR dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for NKTR dated on 2019-08-08: Nektar Therapeutics Shares Fall 33% Following Q2 Earnings Report

Financial news for NKTR dated on 2019-08-08: Nektar Shares Resume Trade, Down 20+%

Financial news for NKTR dated on 2019-08-08: Nektar Therapeutics Says it Has Experienced Delays With its Bempegaldesleukin Program, Says Will Discuss on the Quarterly Conference Call at 5pm ET

Financial news for NKTR dated on 2019-08-08: Nektar Therapeutics Q2 EPS \$(0.63) Beats \$(0.8) Estimate, Sales \$23.3M Miss \$26.65M Estimate

Financial news for NKTR dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for NKTR dated on 2019-08-07: Stocks That Fell Through 52-Week Lows Wednesday

Financial news for NKTR dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for NKTR dated on 2019-08-01: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for NKTR dated on 2019-08-01: Nektar Therapeutics And Bristol-Myers Squibb Announce FDA Breakthrough Therapy Designation For NKTR-214 In Combination With Opdivo For The Treatment Of Patients With Untreated Advanced Melanoma

Financial news for NKTR dated on 2019-07-31: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Financial news for NKTR dated on 2019-07-30: Nektar Therapeutics Option Alert: Aug 16 \$32 Calls Sweep (2) near the Ask: 800 @ \$0.526 vs 447 OI; Earnings 8/7 After Close [est] Ref=\$28.6699

Financial news for NKTR dated on 2019-07-30: New 52-Week Lows for Tuesday Morning

Financial news for NKTR dated on 2019-07-29: Nektar Therapeutics shares are trading lower on seemingly no company-specific news.

Financial news for NKTR dated on 2019-07-26: Nektar Therapeutics Option Alert: Jan 17 \$40 Calls at the Ask: 5000 @ \$2.3 vs 436 OI; Earnings 8/7 After Close [est]
Ref=\$30.0891

Financial news for NKTR dated on 2019-07-25: Nektar Therapeutics shares are trading lower after the company's 8-K showed that the FDA would postpone the product specific advisory committee meeting for Opioid Analgesics. The FDA said the reason for postponement was not unique to Nektar.

Financial news for NKTR dated on 2019-07-25: UPDATE: Nektar Notes FDA Letter States Reason For Postponement Not Unique To Nektar; FDA Will Continue To Review NDA For NKTR-181 According To Existing PDUFA Timeline

Financial news for NKTR dated on 2019-07-25: Nektar Therapeutics 8-K Shows Co. Received General Advice Letter From FDA For New Drug Application On NKTR-181: FDA Will Postpone Product-Specific Advisory Committee Meetings For Opiod Analgesics

Financial news for NKTR dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for NKTR dated on 2019-06-13: The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetrphase Downsizes

Financial news for NKTR dated on 2019-06-13: Nektar Therapeutics Reports Results Of Phase 1a Study Of NKTR-358 As T Regulatory Cell Stimulator To Be Presented At EULAR

Financial news for NKTR dated on 2019-06-09: BioXcel Pharmaceuticals CEO On Drug Pipeline, How AI Is Changing Sector

Financial news for NKTR dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for NKTR dated on 2019-06-04: 66 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-06-03: 51 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2019-06-03: Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.

Financial news for NKTR dated on 2019-06-03: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for NKTR dated on 2019-06-01: Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at #ASCO19; 42% of Patients Achieved a Maximum Reduction of 100% in Target Lesions

Financial news for NKTR dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for NKTR dated on 2019-05-23: Trovagene Reports Research Collab With Nektar Therapeutics To Evaluate Efficacy Of Combo Of Onvansertib, ONZEALD In Models Of Colorectal Cancer

Financial news for NKTR dated on 2019-05-23: Nektar Therapeutics Highlights Launch Of Inheris Biopharma

Financial news for NKTR dated on 2019-05-22: Jim Cramer Weighs In On Nektar, L Brands And More

Financial news for NKTR dated on 2019-05-16: 5 ASCO Abstracts That Moved Stocks

Financial news for NKTR dated on 2019-05-15: Nektar Therapeutics Highlights 5 Accepted Abstracts At ASCO

Financial news for NKTR dated on 2019-05-13: Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.

Financial news for NKTR dated on 2019-05-08: Nektar Therapeutics Q1 EPS \$(0.68) Down

From \$(0.6) YoY, Sales \$28.222M Down From \$38.018M YoY

Financial news for NKTR dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for NKTR dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for NKTR dated on 2019-04-16: Jim Cramer Weighs In On Oracle, Bluebird Bio And More

Financial news for NKTR dated on 2019-04-02: Nektar Therapeutics Highlights Presentation Of Preclinical Data On Its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019

Financial news for NKTR dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for NKTR dated on 2019-04-01: Nektar Therapeutics, Vaccibody Highlight Presentation Of Preclinical Data For VB10.NEO At AACR Meeting

Financial news for NKTR dated on 2019-03-04: BioXcel Therapeutics Announces Addition Of Merck KGaA, Darmstadt, Germany, And Pfizer To Clinical Collaboration With Nektar For Development Of Triple-combination Therapy In Pancreatic Cancer

Financial news for NKTR dated on 2019-03-04: BioXcel Therapeutics Announces Merck and Pfizer Join its Clinical Collaboration with Nektar Therapeutics to Evaluate a Triple Therapy for Pancreatic Cancer

Financial news for NKTR dated on 2019-03-04: 81 Biggest Movers From Friday

Financial news for NKTR dated on 2019-03-01: Nektar Therapeutics Highlights Presentation Of Preliminary Immune Activation, Safety And Clinical Activity Data From The Ongoing Dose-Escalation Stage Of REVEAL Study At 2019 ASCO-SITC Meeting

Financial news for NKTR dated on 2019-03-01: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for NKTR dated on 2019-02-28: Nektar Therapeutics Q4 EPS \$(0.57) Misses \$(0.54) Estimate, Sales \$39.8M Miss \$45.92M Estimate

Financial news for NKTR dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for NKTR dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for NKTR dated on 2019-02-22: BMO Capital Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces \$75 Price Target

Financial news for NKTR dated on 2019-02-15: UPDATE: Nektar Says 'translational research demonstrated that in patients with the highest unmet medical need...treatment with the combo resulted in 70% of patients converting to PD-L1 positive expressors'

Financial news for NKTR dated on 2019-02-15: UPDATE: Nektar Says Stage IV With Median Age 70 Cohort 'was generally well tolerated with no Grade 4 or 5 adverse events reported'

Financial news for NKTR dated on 2019-02-15: UPDATE: Nektar Says 'responses were observed regardless of baseline PD-L1 expression and no relapses occurred'

Financial news for NKTR dated on 2019-02-15: UPDATE: Nektar Says Prelim. Results From PIVOT-02 Study Of NKTR-214 Combo Shares In Poster Presentation Fri., Showed 'important response rates, including complete responses, in patients who were cisplatin-ineligible or refused standard of care'

Financial news for NKTR dated on 2019-02-15: Nektar Therapeutics Issues Press Release Highlighting Presentation Of New Data For NKTR-214 In Combo With Nivolumab For Advanced, Metastatic Urothelial Carcinoma At ASCO GU

Financial news for NKTR dated on 2019-02-15: The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Financial news for NKTR dated on 2019-02-13: 58 Biggest Movers From Yesterday

Financial news for NKTR dated on 2019-02-12: 44 Stocks Moving In Tuesday's Mid-Day

Session

Financial news for NKTR dated on 2019-02-12: Nektar Therapeutics shares are trading lower after the company announced a 48% response rate for its urothelial cancer treatment versus 60% previously.

Financial news for NKTR dated on 2019-02-12: The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

Financial news for NKTR dated on 2019-02-04: Nektar Therapeutics Option Alert: Oct 18 \$65 Calls at the Ask: 500 @ \$3.351 vs 0 OI; Earnings 2/28 After Close [est] Ref=\$42.625

Financial news for NKTR dated on 2019-01-10: Notable Biotech Source, Twitter Account Andy Biotech, Tweets 'Cytokines continue to be one of the hottest thing in #immunotherapy...and a new startup @neoleukin -> watch out \$NKTR \$THOR'

Financial news for NKTR dated on 2019-01-08: Nektar Therapeutics shares are trading higher after the company outlined a research collaboration with Gilead at JP Morgan's healthcare conference.

Financial news for NKTR dated on 2019-01-08: UPDATE: Nektar Says Gilead Will Be Responsible For Preclinical Studies, Costs

Financial news for NKTR dated on 2019-01-08: UPDATE: Nektar Research Collab With Gilead Will Be For Exploration Of Combo Between Co.'s NKTR-225 And Gilead's Effector-Memory T Cells With Antiretroviral Therapies

Financial news for NKTR dated on 2019-01-08: Nektar Therapeutics 8-K Shows Pres, CEO Will Make Presentation At JP Morgan Healthcare Conference; Will Outline Research Collab With Gilead; Will Show \$1.92B In Cash, Equivalents as Of Dec. 31, 2018

Financial news for NKTR dated on 2018-12-26: 6 Valuable Pipeline Drugs With Upcoming Catalysts

Financial news for NKTR dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for NKTR dated on 2018-12-13: Nektar Therapeutics shares are trading up 3% after Goldman Sachs initiated with a Buy and announced a \$62 price target.

Financial news for NKTR dated on 2018-12-13: Goldman Sachs Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces \$62 Price Target

Financial news for NKTR dated on 2018-11-21: Nektar Therapeutics Option Alert: Jan 18 \$40 Calls at the Ask: 1839 @ \$2.8 vs 1055 OI; Ref=\$37.19

Financial news for NKTR dated on 2018-11-13: Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to \$86

Financial news for NKTR dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for NKTR dated on 2018-11-08: Jefferies Maintains Buy on Nektar Therapeutics, Lowers Price Target to \$73

Financial news for NKTR dated on 2018-11-07: Nektar Therapeutics Q3 EPS \$(0.56) Beats \$(0.63) Estimate, Sales \$27.762M Beat \$26.08M Estimate

Financial news for NKTR dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for NKTR dated on 2018-11-07: Nektar Therapeutics Q3 Earnings Outlook

Financial news for NKTR dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NKTR dated on 2018-10-23: Nektar Therapeutics Option Alert: Nov 16 \$40 Calls Sweep (38) above Ask!: 674 @ \$3.898 vs 788 OI; Earnings 11/6 After Close [est] Ref=\$38.45

Financial news for NKTR dated on 2018-10-23: 58 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-10-05: 3 Screens That Hint At Which Stocks May Outperform In Q4

Financial news for NKTR dated on 2018-10-05: Jim Cramer Gives His Opinion On Anheuser-Busch, Nektar, Walker & Dunlop And More

Financial news for NKTR dated on 2018-10-02: 48 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-10-01: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2018-10-01: Nektar Therapeutics shares are down 7.6% as traders circulate report from short seller Plainview; Report highlights value of stock at 'zero'.

Financial news for NKTR dated on 2018-10-01: Traders Circulating Report From Short Seller Plainview On Nektar Therapeutics, Highlights Value Of Stock At 'Zero'

Financial news for NKTR dated on 2018-09-24: BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer

Financial news for NKTR dated on 2018-08-08: Nektar Therapeutics Q2 EPS \$5.33 Beats \$5.22 Estimate, Sales \$1.088B Beat \$1.03B Estimate

Financial news for NKTR dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for NKTR dated on 2018-08-08: Earnings Scheduled For August 8, 2018

Financial news for NKTR dated on 2018-07-30: Nektar Therapeutics Reports New Drug Application For NKTR-181 Accepted For Review By FDA

Financial news for NKTR dated on 2018-06-26: IsoPlexis Reports Research Partnership with Nektar Therapeutics

Financial news for NKTR dated on 2018-06-19: 21 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NKTR dated on 2018-06-14: Nektar Up 3% Since 10 a.m. Release On Presentation Of Preclinical Comments For NKTR-181 This Week; Mizuho Analyst, Asked If Release Could Have Moved Stock, Said 'NKTR-181 accounts for \$2-3/share in my valuation, so I don't think it can move the stock'

Financial news for NKTR dated on 2018-06-14: Nektar Therapeutics Option Alert: Jan 18 \$60 Puts at the Bid: 600 @ \$15.651 vs 393 OI; Earnings 8/7 After Close [est] Ref=\$54.08

Financial news for NKTR dated on 2018-06-11: Benzinga's Top Upgrades, Downgrades For June 11, 2018

Financial news for NKTR dated on 2018-06-11: H.C. Wainwright Downgrades Nektar Therapeutics to Neutral, Announces \$54 Price Target

Financial news for NKTR dated on 2018-06-10: The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Financial news for NKTR dated on 2018-06-08: 45 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-06-06: Nektar Therapeutics Shares Volatile Here; Co. Mulling Possible NKTR-181 Licensing To Commercial Partners, Also Considering Other Strategic Structural Alternatives

Financial news for NKTR dated on 2018-06-06: Nektar Therapeutics Option Alert: Jun 15 \$60 Puts Sweep (2) near the Ask: 2825 @ \$1.801 vs 4083 OI; Ref=\$64.32

Financial news for NKTR dated on 2018-06-05: Nektar Therapeutics Option Alert: Nov 16 \$45 Puts at the Bid: 2300 @ \$5.8 vs 322 OI; Ref=\$56.64

Financial news for NKTR dated on 2018-06-05: Shares Of Nektar Spike To High Of \$56.68, Now Up ~7.5% On The Day

Financial news for NKTR dated on 2018-06-05: Nektar Therapeutics Option Alert: Nov 16 \$75 Puts at the Bid: 6312 @ \$25.15 vs 6313 OI; Ref=\$55.44

Financial news for NKTR dated on 2018-06-05: 44 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-06-04: Benzinga Pro's Top 10 Most-Searched Tickers For The Evening Of Mon., Jun. 4

Financial news for NKTR dated on 2018-06-04: Nektar Therapeutics Shares Down ~43.5% Ahead Of Close Following Prelim. Data From Co., Bristol-Myers Related To NKTR-214 In Combo With Opdivo

Financial news for NKTR dated on 2018-06-04: Mid-Afternoon Market Update: Dow Up 180 Points; Nektar Therapeutics Shares Plummet

Financial news for NKTR dated on 2018-06-04: 5 Biotech Stocks Moving On ASCO Presentations

Financial news for NKTR dated on 2018-06-04: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2018-06-04: Mid-Day Market Update: Crude Oil Down 1.5%; American Electric Technologies Shares Spike Higher

Financial news for NKTR dated on 2018-06-04: Nektar Therapeutics Option Alert: Jan 18, 2019 \$55 Puts at the Ask: 612 @ \$13.6 vs 113 OI; Ref=\$53.7

Financial news for NKTR dated on 2018-06-04: Mid-Morning Market Update: Markets Open Higher; Palo Alto Networks Beats Q3 Estimates

Financial news for NKTR dated on 2018-06-04: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for NKTR dated on 2018-06-04: 40 Biggest Movers From Friday

Financial news for NKTR dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for NKTR dated on 2018-06-02: Nektar,ristol-Myers Squibb Announce Preliminary Data for NKTR-214 in Combination with Opdivo for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at #ASCO2018

Financial news for NKTR dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for NKTR dated on 2018-05-31: Nektar Therapeutics Reports Submission Of NDA For NKTR-181 For Treatment Of Chronic Low Back Pain In Adults Patients New To Opioid Therapy

Financial news for NKTR dated on 2018-05-30: Syndax Pharma, Nektar Therapeutics Report Non-Exclusive, Clinical Collab. To Evaluate Safety, Efficacy Of Nektar's NKTR-214 In Combo With Syndax's Entinostat In Patients With Metastatic Melanoma Previously Progressed On Treatment With Anti-PD-1 Agent

Financial news for NKTR dated on 2018-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for NKTR dated on 2018-05-18: 48 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-05-17: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for NKTR dated on 2018-05-17: Nektar Therapeutics Late Wednesday Announced Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Financial news for NKTR dated on 2018-05-10: Nektar Therapeutics Q1 EPS \$(0.60) May Not Compare To \$0.09 Estimate, Sales \$38.02M Miss \$165.34M Estimate

Financial news for NKTR dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for NKTR dated on 2018-05-08: Nektar Therapeutics Reports Initiation Of Phase 1b Study Of NKTR-358 For Patients With Systemic Lupus Erythematosus

Financial news for NKTR dated on 2018-05-08: Jim Cramer Advises His Viewers On Prestige Brands, CVS Health And More

Financial news for NKTR dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for NKTR dated on 2018-04-24: Nektar Reports New Clinical Collaboration With Takeda To Evaluate Co.'s NKTR-214 With Takeda's TAK-659 As Regimen For Multiple Cancer Settings

Financial news for NKTR dated on 2018-04-20: Seaport Global Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces \$120.00 Price Target

Financial news for NKTR dated on 2018-04-17: 38 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-04-16: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2018-04-16: Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at #AACR18

Financial news for NKTR dated on 2018-04-13: PiperJaffray Reinstates Overweight on Nektar Therapeutics, Announces \$125.00

Financial news for NKTR dated on 2018-04-11: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors

Financial news for NKTR dated on 2018-04-10: 40 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-04-06: Biotech Stocks Underperforming The Market, With The SPDR Biotech ETF (XBI) Down 3.2%, Stocks Down Hardest Include: ALNA -20.3%, JNCE -9%, NKTR -10.9%, MRTX -10.3%, ARMO -8.7%

Financial news for NKTR dated on 2018-04-06: Benzinga's Top Analyst Calls From April 6, 2018

Financial news for NKTR dated on 2018-04-06: Mizuho Out Positive On Nektar Therapeutics Says Incyte's epacadostat Phase 3 Failure Is A Positive For The Company, Believes This News Raises The Possibility Of A Takeout By BMS In The Coming Months

Financial news for NKTR dated on 2018-04-06: Hearing Mizuho Raised Nektar Price Target From \$89 To \$103

Financial news for NKTR dated on 2018-04-06: 24 Stocks Moving In Friday's Mid-Day Session

Financial news for NKTR dated on 2018-04-06: '\$NKTR is the new \$INCY. Anyone worried about that now?' -Adam Feuerstein Tweet

Financial news for NKTR dated on 2018-04-03: Nektar Therapeutics Announces Bristol-Myers' Collaboration Effective Today, Resulting In Nektar's Receipt Of \$1B Upfront Cash Payment

Financial news for NKTR dated on 2018-04-02: Benzinga's Top Upgrades, Downgrades For April 2, 2018

Financial news for NKTR dated on 2018-04-02: H.C. Wainwright Assumes Nektar Therapeutics at Buy, Announces \$125 Price Target

Financial news for NKTR dated on 2018-04-01: The S&P 500's Biggest Gainers And Losers In A Turbulent First Quarter

Financial news for NKTR dated on 2018-03-06: An Eventful February Took Its Toll On TD Ameritrade's Investor Index

Financial news for NKTR dated on 2018-03-05: 42 Biggest Movers From Friday

Financial news for NKTR dated on 2018-03-02: Mid-Afternoon Market Update: Nektar Therapeutics Gains After Q4 Results; Foot Locker Shares Plummet

Financial news for NKTR dated on 2018-03-02: Nektar Therapeutics Shares Up 23.2% After Co. Reported Late Thursday Q4 Earnings Beat

Financial news for NKTR dated on 2018-03-02: 32 Stocks Moving In Friday's Mid-Day Session

Financial news for NKTR dated on 2018-03-01: Nektar Therapeutics Reports Q4 EPS \$(0.21) vs \$(0.35) Est., Sales \$95.5M May Not Compare to \$36.98M Est.

Financial news for NKTR dated on 2018-03-01: Nektar Therapeutics Q4 Earnings Preview

Financial news for NKTR dated on 2018-02-25: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for NKTR dated on 2018-02-14: Adam Feuerstein Tweet:For \$BMJ -- Paying a ton for NKTR-214 doesn't exactly inspire confidence in Opdivo business, as is. What is lurking under the hood of the -227 study we haven't seen?

Financial news for NKTR dated on 2018-02-14: Bristol-Myers Squibb, Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist, NKTR-214; Nektar To Pay \$1.85B Upfront Comprised Of \$1B In Cash & Purchase Of 8.28M Shares At \$102.60/Share

Financial news for NKTR dated on 2018-02-07: Nektar Therapeutics Shares Fall To Low Of \$70.72/Share Down 9.3%

Financial news for NKTR dated on 2018-02-02: Shares of Alkermes Trade Higher Following Chatter That Nektar Therapeutics Has Takeover Interest from Larger Drug Makers, Alkermes' Products Have Similarities to Nektar

Financial news for NKTR dated on 2018-02-02: Watching Shares of Nektar Therapeutics As Co. Said To Be Exploring A Sale, Unconfirmed

Financial news for NKTR dated on 2018-02-01: Nektar Shares Continuing Higher Over \$85 Resistance Level, Now Up 3.3% For Session To Over \$86; Stock Up 48% Since Jan. 9; Saw Notable Option Activity On Jan. 10: Jan. \$65, \$70 Calls, Feb. \$65 Calls

Financial news for NKTR dated on 2018-02-01: Nektar Therapeutics Shares Up ~3% Over Last Few Mins, Bouncing Off \$83 Level; Stock Up 2.1% For Session

Financial news for NKTR dated on 2018-01-19: Here's Why Nektar Stock Skyrocketed Almost 500% In A Year

Financial news for NKTR dated on 2018-01-10: Nektar Option Alert: Feb 16 \$65 Calls Sweep (16) at the Ask: 600 @ \$7.201 vs 450 OI; Earnings 2/28 After Close [est] Ref=\$67.7

Financial news for NKTR dated on 2018-01-10: Nektar Option Alert: Jan 19 \$65 Calls Sweep (6) at the Bid: 500 @ \$7.75 vs 5685 OI; Earnings 2/28 After Close [est] Ref=\$73.05

Financial news for NKTR dated on 2018-01-10: 40 Biggest Movers From Yesterday

Financial news for NKTR dated on 2018-01-09: STAT News' Adam F. Tweets: '\$NKTR The irrational exuberance for NKTR-214 continues, I presume? #JPM18'

Financial news for NKTR dated on 2018-01-09: Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet

Financial news for NKTR dated on 2018-01-09: Mid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares Drop

Financial news for NKTR dated on 2018-01-09: Mid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses Views

Financial news for NKTR dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for NKTR dated on 2017-12-15: Nektar Therapeutics 8-K Filing Shows Co. Received Formal Notice Of Termination From Bayer For Co-Development, License, Co-Promotion Deal

Financial news for NKTR dated on 2017-11-28: Piper Jaffray Healthcare Conference 2017 Begins Today, Presenters Include: Civitas Solutions, Insulet, ACADIA Healthcare, Nektar Therapeutics, Quidel, and Arrowhead Pharmaceuticals

Financial news for NKTR dated on 2017-11-24: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for NKTR dated on 2017-11-24: A Peek Into The Markets: U.S. Stock Futures Rise On Black Friday

Financial news for NKTR dated on 2017-11-24: UPDATE: Nektar Says Co. Will Not Incur ~\$25M-\$30M In Commercial Manufacturing Scale-Up, Readiness Costs Over Next 12-18 Mos.

Financial news for NKTR dated on 2017-11-24: UPDATE: Nektar Says Will Incur \$3-\$4M Of Wind-Down Costs Related To Conclusion Of Co.'s Activities, Commitments To CMOs

Financial news for NKTR dated on 2017-11-24: UPDATE: Nektar Highlights Bayer Announced Phase 3 Amikacin Inhale Did Not Meet Primary Or Key Secondary Endpoints; Co. Does Not Expect Bayer To Move Forward With Program, Does Not Expect Any Further Performance Obligations

Financial news for NKTR dated on 2017-11-24: Nektar Therapeutics 8-K Shows Co. Retained Rights Under '07 Deal With Bayer For Amikacin Inhale For Aerosolized Treatment Of Gram Negative Pneumonias

Financial news for NKTR dated on 2017-11-24: Bayer Announces Phase Iii Study With Amikacin Inhale In Intubated And Mechanically Ventilated Patients With Gram-Negative Pneumonia Does Not Meet Primary Endpoint Of Superiority

Financial news for NKTR dated on 2017-11-22: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NKTR dated on 2017-11-14: 34 Biggest Movers From Yesterday

Financial news for NKTR dated on 2017-11-13: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for NKTR dated on 2017-11-13: Analyst: Nektar Has A Handful Of Milestones Ahead In 2018

Financial news for NKTR dated on 2017-11-13: Canaccord Genuity Maintains Buy on Nektar Therapeutics, Raises Price Target to \$50.00

Financial news for NKTR dated on 2017-11-13: Mid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q4 Expectations

Financial news for NKTR dated on 2017-11-13: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for NKTR dated on 2017-11-13: Nektar Therapeutics +20% Premarket \$39; Co Announced Presentation of Encouraging Data from PIVOT-02 Phase 1/2 Study Showing Potential Benefits Presented at SITC 2017

Financial news for NKTR dated on 2017-11-12: Nektar Therapeutics, Bristol-Myers Squibb Announce First Presentation of Data from PIVOT-02 Phase 1/2 Study Showing Potential Benefits Presented at SITC 2017

Financial news for NKTR dated on 2017-11-09: Benzinga's Top Upgrades, Downgrades For November 9, 2017

Financial news for NKTR dated on 2017-11-09: Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces \$35.00 Price Target

Financial news for NKTR dated on 2017-11-09: 57 Biggest Movers From Yesterday

Financial news for NKTR dated on 2017-11-08: 4 Q3 Earnings Winners Breaking Out

Financial news for NKTR dated on 2017-11-08: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NKTR dated on 2017-11-08: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NKTR dated on 2017-11-07: Nektar Therapeutics Reports Q3 EPS \$0.37 vs. \$(0.32) In Same Qtr. Last Year, Sales \$152.928M vs \$36.336M YoY

Financial news for NKTR dated on 2017-11-07: Benzinga's Top Upgrades, Downgrades For November 7, 2017

Financial news for NKTR dated on 2017-11-07: Cowen & Co. Initiates Coverage On Nektar Therapeutics with Outperform Rating

Financial news for NKTR dated on 2017-11-06: Nektar Therapeutics Option Alert: Nov 17 \$25 Calls Sweep (7) at the Ask: 510 @ \$1.122 vs 880 OI; Ref=\$23.91

Financial news for NKTR dated on 2017-10-11: Watch These 8 Huge Put Purchases In Wednesday Trade

Financial news for NKTR dated on 2017-10-10: Benzinga's Option Alert Recap From October 10

Financial news for NKTR dated on 2017-10-10: Nektar Therapeutics Option Alert: Jan 19 \$18 Puts Sweep (30) at the Bid: 603 @ \$0.65 vs 91 OI; Ref=\$23.34

Financial news for NKTR dated on 2017-09-27: Benzinga's Top Upgrades, Downgrades For September 27, 2017

Financial news for NKTR dated on 2017-09-27: Mizuho Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces \$30.00 Price Target

Financial news for NKTR dated on 2017-09-12: Nektar Therapeutics Reports Initiation Of PROPEL Study To Evaluate Combo Of NKTR-214 With TECENTRIQ Or KEYTRUDA

Financial news for NKTR dated on 2017-08-08: Nektar Therapeutics Reports Q2 EPS \$(0.39) vs \$(0.37) Est., Sales \$34.589M vs \$34.23M Est.

Financial news for NKTR dated on 2017-08-07: Benzinga's Top Upgrades, Downgrades For August 7, 2017

Financial news for NKTR dated on 2017-08-07: H.C. Wainwright Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces \$31.00 Price Target

Financial news for NKTR dated on 2017-07-27: Are Options Traders Betting On A Big Move In Nektar Stock?

Financial news for NKTR dated on 2017-07-24: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for NKTR dated on 2017-07-24: Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358

Financial news for NKTR dated on 2017-07-24: Nektar Therapeutics Halted, News Pending

Financial news for NKTR dated on 2017-07-21: Nektar Therapeutics' Onzeald Recommended for Approval by the EU Medicines Agency

Financial news for NKTR dated on 2017-07-18: Nektar Therapeutics Offers Topline Data From Human Abuse Potential Study For NKTR-181: 'shows significantly less abuse potential compared to oxycodone'

Financial news for NKTR dated on 2017-07-18: Nektar Reports Topline Data From Human Abuse Potential Study for NKTR-181 Shows Significantly Less Abuse Potential vs Oxycodone

Financial news for NKTR dated on 2017-06-05: Nektar Reports New Clinical Data Showing 2 Studies of NKTR-214 at ASCO

Financial news for NKTR dated on 2017-06-05: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for NKTR dated on 2017-06-02: Option Alert: Nektar Therapeutics Jun 23.0 Calls Sweep: 600 @ ASK \$0.35: 768 traded vs 43 OI: Earnings 8/2 After Close (est) \$20.04 Ref

Financial news for NKTR dated on 2017-05-22: Nektar Therapeutics Reports New Research Collaboration with Takeda Pharma for Exploration of Combo Cancer Therapy Approaches with NKTR-214, 5 Takeda Cancer Therapy Compounds

Financial news for NKTR dated on 2017-05-09: Nektar Therapeutics Reports Q1 EPS \$(0.42) vs \$(0.41) Est., Sales \$24.72M vs \$26.8M Est.

Financial news for NKTR dated on 2017-04-17: Watch These 8 Huge Call Purchases In Monday Trade

Financial news for NKTR dated on 2017-04-13: Benzinga's Option Alert Recap From April 13

Financial news for NKTR dated on 2017-04-13: Option Alert: Nektar May 15.0 Calls Sweep: 1999 @ ASK \$3.80: 2501 traded vs 5516 OI: Earnings 5/3 After Close [est] \$18.32 Ref

Financial news for NKTR dated on 2017-03-20: Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide

Financial news for NKTR dated on 2017-03-20: Roth Capital Raises Nektar Therapeutics Price Target From \$23 To \$31 Citing Powerful Efficacy In NKTR-181 Data

Financial news for NKTR dated on 2017-03-20: 12 Biggest Mid-Day Gainers For Monday

Financial news for NKTR dated on 2017-03-20: Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop

Financial news for NKTR dated on 2017-03-20: Nektar Hurting Shorts With Positive Results From NKTR-181 Study

Financial news for NKTR dated on 2017-03-20: Mid-Morning Market Update: Markets Mostly Flat; Washington Companies Proposes To Acquire Dominion Diamond

Financial news for NKTR dated on 2017-03-20: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for NKTR dated on 2017-03-20: Nektar Therapeutics Resumes Trading at 8:00 AM ET

Financial news for NKTR dated on 2017-03-20: NKTR-181 Meets Primary, Secondary Endpoints in Phase 3 SUMMIT-07 Study

Financial news for NKTR dated on 2017-03-20: Nektar Therapeutics Halted News Pending

Financial news for NKTR dated on 2017-03-02: 25 Biggest Mid-Day Gainers For Thursday

Financial news for NKTR dated on 2017-03-01: Nektar Therapeutics Reports Q4 EPS \$(0.28) vs. \$(0.26), Sales \$37.5M vs. \$40.8M Est.

Financial news for NKTR dated on 2017-01-23: Benzinga's Option Alert Recap From January 23

Financial news for NKTR dated on 2017-01-23: Option Alert: Nektar Therapeutics Feb 13.0 Calls Sweep: 952 @ ASK \$0.55: 974 traded vs 100 OI: Earnings 3/1 After Close (est) \$12.12 Ref

Financial news for NKTR dated on 2016-12-27: Why The Last Week Of 2016 Could Be Big For Biotech Catalysts

Financial news for NKTR dated on 2016-12-06: Watch These 7 Huge Put Purchases In Tuesday Trade

Financial news for NKTR dated on 2016-12-05: Option Alert: NKTR May17 10.0 Puts Sweep: 828 @ ASK \$1.50: 6155 traded vs 2588 OI: Earnings 3/1 After Close (est) \$12.73 Ref

Financial news for NKTR dated on 2016-11-09: Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer 2016 Annual Meeting

Financial news for NKTR dated on 2016-11-08: Benzinga's Top Initiations

Financial news for NKTR dated on 2016-11-08: Aegis Capital Initiates Coverage On Nektar Therapeutics - Common Stock at Buy, Announces \$21.00

Financial news for NKTR dated on 2016-11-03: Nektar Therapeutics Reports Q3 Loss/Share \$0.32 vs Est Loss/Share \$0.36, Rev \$36.336M vs \$32.42M Est

Financial news for NKTR dated on 2016-10-26: Nektar Therapeutics Insider R. Scott Green Direct Acquired 15,000 Common Shares At \$13.50/Shr On Oct 24, Now Holds 121,333 Shares - Form4

Financial news for NKTR dated on 2016-10-19: 15 Biggest Mid-Day Losers For Wednesday

Financial news for NKTR dated on 2016-10-19: 16 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NKTR dated on 2016-10-17: Nektar Reports Offering of \$175M in Common Shares

Financial news for NKTR dated on 2016-09-30: Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy

Financial news for NKTR dated on 2016-09-30: Brean Capital Assumes Nektar Therapeutics at Buy, Announces \$23.00 PT

Financial news for NKTR dated on 2016-09-28: 7 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for NKTR dated on 2016-09-27: Bristol-Myers, Nektar Therapeutics Report Oncology Clinical Collaboration to Evaluate Combo of Opdivo, NKTR-214

Financial news for NKTR dated on 2016-08-03: Nektar Therapeutics Reports Q2 Loss -\$0.36 vs Est Loss/Share -\$0.33, Rev \$32.768M vs \$30.47M Est

Financial news for NKTR dated on 2016-06-06: Nektar Therapeutics Reports Preclinical Data For NKTR-214

Financial news for NKTR dated on 2016-06-02: Nektar Therapeutics Names John Nicholson COO, Gil Labrucherie CFO

Financial news for NKTR dated on 2016-06-01: Brean Weighs In On Nektar ONZEALD Deal

Financial news for NKTR dated on 2016-06-01: Nektar Therapeutics Reports Signing of European Licensing Deal for ONZEALD with Daiichi Sankyo Europe

Financial news for NKTR dated on 2016-05-03: Nektar Reports Q1 EPS \$(0.14) Vs Est \$(0.23), Sales \$58.882M Vs Est \$43.78M

Financial news for NKTR dated on 2016-04-18: Nektar Therapeutics Presents Pre-Clinical Data Combining NKTR 214 With Checkpoint Blockade

Financial news for NKTR dated on 2016-04-18: Nektar Reports Preclinical Data

Presented at AACR, Showed Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition

Financial news for NKTR dated on 2016-04-01: Nektar Shares Quiet Following Probes Reporter Tweet: 'Nektar Therapeutics \$NKTR Confirmed, Undisclosed SEC Investigation. <http://buff.ly/1Sqf7uM>'

Financial news for NKTR dated on 2016-03-01: Nektar Therapeutics Reports Q4 EPS \$(0.40) Vs Est \$(0.42), Sales \$39.4M Vs Est \$28.82M

Financial news for NKTR dated on 2016-02-25: Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings

Financial news for NKTR dated on 2016-02-01: UPDATE: Nektar Results for NKTR-214 Show Favorable Safety Profile in Non-Human Primates

Financial news for NKTR dated on 2016-02-01: Nektar Therapeutics Offers Preclinical Results for NKTR-214: Shows Durable Anti-Tumor Efficacy, Safety, Immune Mechanism in Multiple Tumor Models

Financial news for NKTR dated on 2016-01-28: Benzinga's Top Initiations

Financial news for NKTR dated on 2016-01-28: Janney Capital Initiates Coverage on Nektar Therapeutics at Buy

Financial news for NKTR dated on 2015-12-29: Stocks Hitting 52-Week Highs

Financial news for NKTR dated on 2015-12-21: Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age, Nearly 73% Treated Patients Experienced Zero Joint Bleeds

Financial news for NKTR dated on 2015-12-08: Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine

Financial news for NKTR dated on 2015-12-07: Baxalta Show Data On ADYNOVATE For New Indications During ASH Conference Meeting

Financial news for NKTR dated on 2015-12-07: Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology Annual Meeting

Financial news for NKTR dated on 2015-11-30: Baxalta Announces U.S. Availability of ADYNOVATE, New Treatment for Adult Patients With Hemophilia A With a Simple, Twice-Weekly Dosing Schedule

Financial news for NKTR dated on 2015-11-27: Endologix, Express, Rockwell Automation Lead After-Hours Movers To Close Holiday Week

Financial news for NKTR dated on 2015-11-14: Baxalta Announces FDA Approval of ADYNOVATE Treatment for Hemophilia A

Financial news for NKTR dated on 2015-11-05: Nektar Therapeutics Reports Q3 EPS \$(0.06) vs. Est. \$(0.24), Rev. \$59.952M vs. Est. \$44.3M

Financial news for NKTR dated on 2015-10-07: Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies

Financial news for NKTR dated on 2015-09-21: Nektar Shows Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models

Financial news for NKTR dated on 2015-09-01: Nektar Announces Receipt of \$40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG(r) (naloxegol) Tablets in Major European Market

Financial news for NKTR dated on 2015-08-25: Market Panic Has Created 'Compelling' Opportunities In Biotech

Financial news for NKTR dated on 2015-08-25: Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics

Financial news for NKTR dated on 2015-08-05: Nektar Therapeutics Reports Inline Q2 Loss \$0.40, Sales \$22.7M Vs Est \$21.49M

Financial news for NKTR dated on 2015-07-16: Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing

for Patients with Hemophilia A

Financial news for NKTR dated on 2015-07-16: Baxalta's BAX 855 Important Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A

Financial news for NKTR dated on 2015-06-24: Mid-Afternoon Market Update: Dow Drops Over 150 Points; Nektar Therapeutics Shares Spike Higher

Financial news for NKTR dated on 2015-06-24: Mid-Day Market Update: Box Surges Following Announcement Of Partnership With IBM On Cloud; Sunedison Semiconductor Shares Fall

Financial news for NKTR dated on 2015-06-24: Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates

Financial news for NKTR dated on 2015-06-24: Morning Market Gainers

Financial news for NKTR dated on 2015-06-24: Benzinga's Top #PreMarket Gainers

Financial news for NKTR dated on 2015-06-02: Nektar and MD Anderson Cancer Center Releases Phase 1/2 Clinical Research Collaboration for NKTR-214

Financial news for NKTR dated on 2015-04-30: Nektar Therapeutics Reports Q1 GAAP EPS \$0.25, Sales \$108.8M

Financial news for NKTR dated on 2015-04-28: Stocks Hitting 52-Week Lows

Financial news for NKTR dated on 2015-04-02: UPDATE: Nektar Is Also Entitled To \$40M Upon First Commercial Sale Of MOVANTI-K In A Major European Country

Financial news for NKTR dated on 2015-04-02: Nektar Announces \$100M Milestone Payment From AstraZeneca

Financial news for NKTR dated on 2015-03-31: MOVANTI-K (Naloxegol) Tablets For Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US

Financial news for NKTR dated on 2015-03-19: Nektar Announces Partner AstraZeneca Reported Co-Commercialization Deal with Daiichi Sankyo for MOVANTI-K in US

Financial news for NKTR dated on 2015-03-18: Morning Market Losers

Financial news for NKTR dated on 2015-03-18: Benzinga's Top #PreMarket Losers

Financial news for NKTR dated on 2015-03-17: Tuesday's After-Hours Movers: Oracle, Papa Murphy's And More

Financial news for NKTR dated on 2015-03-17: PREVIEW: Nektar Therapeutics to Resume Trading at 5:50 PM ET

Financial news for NKTR dated on 2015-03-17: Nektar Announces Topline Results for NKTR-102 Trial In Press Release

Financial news for NKTR dated on 2015-03-17: UPDATE: Nektar Says Will Explore Potential Regulatory Pathways in US, Europe

Financial news for NKTR dated on 2015-03-17: Nektar Announces Topline Results for NKTR-102 Trial, Shows Did Not Achieve Statistical Significance

Financial news for NKTR dated on 2015-03-17: Nektar Shares Halted News Pending

Financial news for NKTR dated on 2015-03-03: Option Alert: Nektar Therapeutics Mar \$12 Call; 110 Contract Trade above Ask @\$1.98; Now 13.07

Financial news for NKTR dated on 2015-02-25: Nektar To Begin Phase 3 SUMMIT-07 Study of NKTR-181

Financial news for NKTR dated on 2015-02-24: Nektar Therapeutics Reports Q4 EPS -\$0.35 Vs Est -\$0.36, Sales \$19.6M Vs Est \$17.27M

Financial news for NKTR dated on 2015-02-20: 5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for NKTR dated on 2015-02-11: Baxter Presents Additional Data from Pivotal Study of BAX 855

Financial news for NKTR dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for NKTR dated on 2015-01-09: What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts

Financial news for NKTR dated on 2015-01-09: 5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years

Financial news for NKTR dated on 2014-12-11: Nektar Offers Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of NKTR-102

Financial news for NKTR dated on 2014-12-01: Nektar Therapeutics's Partner Baxter Intl. Inc. Submits Application For US FDA Approval Of BAX 855

Financial news for NKTR dated on 2014-11-24: Nektar Therapeutics Announces The FDA Granted QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation

Financial news for NKTR dated on 2014-11-20: Nektar Presents Preclinical Study Findings for Etirinotecan Pegol

Financial news for NKTR dated on 2014-11-06: Nektar Therapeutics Reports Q3 EPS of \$0.53 vs \$0.39 Est; Revenue of \$132.90M vs \$123.20M Est

Financial news for NKTR dated on 2014-09-26: Nektar Reports Positive Opinion from CHMP on MOVENTIG for Treatment of Adults with Opioid-Induced Constipation

Financial news for NKTR dated on 2014-09-19: Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting

Financial news for NKTR dated on 2014-09-16: Brean Capital Maintains Buy on Nektar Therapeutics, Raises PT to \$20.00

Financial news for NKTR dated on 2014-09-16: UPDATE: Nektar Shares Bouncing, Stock Now Up 1.8%

Financial news for NKTR dated on 2014-09-16: Shares of Nektar Resume Trade, Stock Now Down 1.4%

Financial news for NKTR dated on 2014-09-16: Shares of Nektar Therapeutics to Resume Trade at 1 p.m. EDT

Financial news for NKTR dated on 2014-09-16: Nektar Therapeutics Confirms FDA Has Approved MOVANTIK Tablets for Treatment of Opioid-Induced Constipation

Financial news for NKTR dated on 2014-09-16: Nektar Therapeutics Spokesperson Says Company Will Issue PR on FDA Approval for Movantik for Opioid-Induced Constipation; Nasdaq Waiting for that PR to Resume Trade in Shares

Financial news for NKTR dated on 2014-09-16: UPDATE: FDA Posts Approval of 'Movantik for Opioid-Induced Constipation'

Financial news for NKTR dated on 2014-09-16: FDA Has Issued Approval for Nektar's Movantik for Opioid-Induced Constipation

Financial news for NKTR dated on 2014-09-16: Nektar Therapeutics Shares Halted News Pending

Financial news for NKTR dated on 2014-07-31: Nektar Therapeutics Reports Q2 EPS of \$(0.26) Which May Not Compare \$(0.37) Est; Revenue of \$28.50M Which May Not Compare \$19.76M Est

Financial news for NKTR dated on 2014-06-26: Ladenburg Thalmann Initiates Coverage on Nektar Therapeutics at Buy, Announces \$20.00 PT

Financial news for NKTR dated on 2014-06-12: Nektar Shares Now Up Nearly 11% Following Resumption

Financial news for NKTR dated on 2014-06-12: Nektar Shares Resume Trade, Now Up 1.6%

Financial news for NKTR dated on 2014-06-12: Nektar Shares to Resume Trade at 4:35 p.m. EDT

Financial news for NKTR dated on 2014-06-12: Nektar Announces FDA Panel Has Recommended No CV Trial for PAMORA Class Including Movantik

Financial news for NKTR dated on 2014-06-12: Sucampo Says FDA Did Not Require Company To Reevaluate Clinical Data Because Action Mechanism For Opioid Constipation is Different

Financial news for NKTR dated on 2014-06-12: Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday

Financial news for NKTR dated on 2014-06-11: Nektar Stock Halted As FDA Will Discuss Receptor Antagonists ~ Bloomberg

Financial news for NKTR dated on 2014-06-11: UPDATE: Nektar Therapeutics, Progenics Halted for FDA Advisory Committees

Financial news for NKTR dated on 2014-06-11: Nektar Therapeutics, Progenics Halted: Pending News

Financial news for NKTR dated on 2014-06-09: Top Healthcare Movers For June 9, 2014

Financial news for NKTR dated on 2014-06-09: Small Pharmaceuticals Rallying Following FDA Report

Financial news for NKTR dated on 2014-06-09: Option Alert Nektar Therapeutics Sept \$13 Call; 2,163 Contracts Traded vs 40 OI: Currently \$11.36

Financial news for NKTR dated on 2014-06-01: Nektar Presents Positive Preclinical Data for NKTR-214 at ASCO 2014

Financial news for NKTR dated on 2014-05-31: Nektar Presents Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin-Refractory High-Grade Glioma at ASCO

Financial news for NKTR dated on 2014-05-19: Nektar Announces Ivan Gergel CMO

Financial news for NKTR dated on 2014-05-07: Nektar Therapeutics Reports Q1 EPS of \$(0.37) vs \$(0.31) Est; Revenue of \$46.20M vs \$38.68M Est

Financial news for NKTR dated on 2014-03-17: AstraZeneca, Nektar Therapeutics: FDA Meeting to Review Mu Opioid Antagonists Is Tentatively Scheduled for June 11-12

Financial news for NKTR dated on 2014-02-27: MKM Partners Downgrades Nektar Therapeutics to Neutral, Maintains \$13.00 PT

Financial news for NKTR dated on 2014-02-26: Nektar Therapeutics Sees FY2014 Sales \$190.0M-195.0M

Financial news for NKTR dated on 2014-02-26: Nektar Therapeutics Reports Q4 EPS of \$(0.41) vs \$(0.37) Est; Revenue of \$31.10M vs \$21.70M Est

Financial news for NKTR dated on 2014-02-06: Option Alert: Nektar Therapeutics Mar/Aug \$13 Call Spread; 2,000 Spread Trade; Currently \$12.29

Financial news for NKTR dated on 2014-01-22: Nektar Therapeutics Prices 8.5M Share Offering at \$12.75/Share

Financial news for NKTR dated on 2014-01-21: Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock

Financial news for NKTR dated on 2014-01-21: Nektar Files Mixed Securities Shelf; Announces Offering of 8.5M Shares

Financial news for NKTR dated on 2014-01-18: Nektar Presents Positive Data from Phase 1 Study of Etritinotecan Pegol in Combination with 5-Fluorouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium

Financial news for NKTR dated on 2014-01-14: Nektar Announces Etritinotecan Pegol (NKTR-102) Passes Interim Efficacy, Could Submit Filings in 2H'15

Financial news for NKTR dated on 2014-01-14: Etritinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

Financial news for NKTR dated on 2013-11-27: UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns

Financial news for NKTR dated on 2013-11-26: Piper Jaffray Initiates Coverage on Nektar Therapeutics at Overweight, Announces \$20.00 PT

Financial news for NKTR dated on 2013-11-26: Piper Jaffray Initiates Coverage on Nektar Therapeutics at Overweight, Announces \$20.00 PT

Financial news for NKTR dated on 2013-11-19: US Stock Futures Edge Lower Ahead Of Earnings

Financial news for NKTR dated on 2013-11-19: Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA

Financial news for NKTR dated on 2013-11-08: Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies Dominate Headlines

Financial news for NKTR dated on 2013-11-07: Nektar Therapeutics Lowers FY2013 Sales Guidance from \$200.0M-210.0M to \$175.0M-185.0M vs \$205.60M Est

Financial news for NKTR dated on 2013-11-07: From Nektar Call: Cutting FY13 Sales Guidance

Financial news for NKTR dated on 2013-11-07: Nektar Therapeutics Reports Q3 EPS of \$(0.14) vs \$(0.22) Est; Revenue of \$60.90M vs \$54.34M Est

Financial news for NKTR dated on 2013-10-08: Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day

Financial news for NKTR dated on 2013-09-30: Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization Application for Naloxegol

Financial news for NKTR dated on 2013-09-27: Market Wrap For Friday, September 27: Dow Ends The Week Negative For First Time In Month

Financial news for NKTR dated on 2013-09-27: Mid-Afternoon Market Update: Cerner Rallies Major Contract While United Airlines Plummet

Financial news for NKTR dated on 2013-09-27: Mid-Day Market Update: Finish Line Gains On Upbeat Results; JC Penney Shares Fall

Financial news for NKTR dated on 2013-09-27: William Blair Reiterates Outperform on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

Financial news for NKTR dated on 2013-09-27: UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

Financial news for NKTR dated on 2013-09-27: Mid-Morning Market Update: Markets Open Lower; BlackBerry Reports Q2 Loss

Financial news for NKTR dated on 2013-09-27: Benzinga's Top Pre-Market Losers

Financial news for NKTR dated on 2013-09-27: Brean Capital Maintains Buy on Nektar Therapeutics, Lowers PT to \$14.00

Financial news for NKTR dated on 2013-09-26: Nektar Shares Resume Trade Down 22%

Financial news for NKTR dated on 2013-09-26: Shares of Netkar to Resume Trade at 4:40PM EDT

Financial news for NKTR dated on 2013-09-26: Nektar Says Results from Phase 2 Trial of NKTR-181 Missed Primary Efficacy Endpoint

Financial news for NKTR dated on 2013-09-26: Nektar Issues Prelim. Topline Results from Phase 2 for NKTR-181, Says Missed Primary Endpoint

Financial news for NKTR dated on 2013-09-26: Nektar Shares Halted News Pending

Financial news for NKTR dated on 2013-09-16: Form 8-K Filing from Nektar Therapeutics Shows AstraZeneca Filed NDA with FDA, AstraZeneca Will Pay Nektar \$70M Milestone on Acceptance of NDA

Financial news for NKTR dated on 2013-09-12: Cowen & Company Initiates Coverage on Nektar Therapeutics at Outperform, Announces \$17.00 PT

Financial news for NKTR dated on 2013-09-10: UPDATE: FDA Will Be Holding an Official Briefing at 12:45PM EDT to Discuss an Undisclosed Topic

Financial news for NKTR dated on 2013-09-10: FDA Traders Considering Admin. Updates Labels on Long-Acting Painkillers

Financial news for NKTR dated on 2013-08-28: Form 8-K from Nektar Therapeutics Shows AstraZeneca Filed NDS with HC for Naloxegol on Aug. 26th

Financial news for NKTR dated on 2013-08-12: Market Wrap For Monday, August 12: Stocks Close Mixed To Start Week

Financial news for NKTR dated on 2013-08-12: Mid-Afternoon Market Update: Silver Continues Strong Rally as Sarepta Remains Down

Financial news for NKTR dated on 2013-08-08: Nektar Therapeutics Sees FY2013 Sales \$200.0M-210.0M vs \$200.80M Est

Financial news for NKTR dated on 2013-08-08: Nektar Therapeutics Reports Q2 EPS of \$(0.37) vs \$(0.44) Est; Revenue of \$33.90M vs \$26.22M Est

Financial news for NKTR dated on 2013-08-01: Option Alert: Nektar Therapeutics September 12 Call; 7,591 Contracts Traded vs 473 Open Interest; Currently \$11.78

Financial news for NKTR dated on 2013-06-19: Market Wrap for Wednesday, June 19: Stocks Plunge as Federal Reserve Discusses Pulling Back Stimulus

Financial news for NKTR dated on 2013-06-19: Mid-Day Market Update: La-Z-Boy Drops On Q4 Results, Nektar Gains

Financial news for NKTR dated on 2013-06-19: Afternoon Market Gainers

Financial news for NKTR dated on 2013-06-19: Nektar Issues Data from Human Abuse Liability Study for NKTR-181

Financial news for NKTR dated on 2013-06-03: Nektar Announces Positive Preclinical Data for NKTR-214

Financial news for NKTR dated on 2013-06-01: Nektar Announces Target-Specific Biomarkers Being Evaluated in Phase 3 BEACON Study of Etilirinecan Pegol

Financial news for NKTR dated on 2013-05-31: Form 8-K Showing Affymax, Lonza Announces Sales Pact to End Supply Deal, Affymax Made \$5.975M Payments to Lonza, Nektar

Financial news for NKTR dated on 2013-05-21: Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013

Financial news for NKTR dated on 2013-05-09: Nektar Therapeutics Reports Q1 EPS of \$(0.48) vs \$(0.42) Est; Revenue of \$23.0M vs \$26.33M Est

Financial news for NKTR dated on 2013-04-19: Stocks to Watch for April 19, 2013

Financial news for NKTR dated on 2013-04-16: Bayer Initiates Phase III Trial of BAY41-6551T, Delivered by a Pulmonary Drug Delivery System Developed by Nektar Therapeutics

Financial news for NKTR dated on 2013-03-01: UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Nektar Therapeutics on Q4 Loss

Financial news for NKTR dated on 2013-03-01: Deutsche Bank Maintains Buy on Nektar Therapeutics, Lowers PT to \$12.00

Financial news for NKTR dated on 2013-02-28: Nektar Therapeutics Sees FY2013 Sales \$200.0M-210.0M vs \$175.20M Est

Financial news for NKTR dated on 2013-02-28: Nektar Therapeutics Reports Q4 EPS of \$(0.46) vs \$(0.44) Est; Revenue of \$21.10M vs \$19.12M Est

Financial news for NKTR dated on 2013-01-15: Lazard Capital Markets Initiated Coverage on Nektar Therapeutics at Buy, Announced \$15.00 PT

Financial news for NKTR dated on 2012-11-14: Mid-Day Market Update: Markets Slump; Facebook Remains Up on Massive Volume

Financial news for NKTR dated on 2012-11-13: UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform

Financial news for NKTR dated on 2012-11-13: Bank of America Maintains Nektar Therapeutics at Underperform, Lowers PT from \$7.50 to \$7

Financial news for NKTR dated on 2012-11-12: Nektar Therapeutics Plunges on FDA Worries, Downgrade

Financial news for NKTR dated on 2012-11-12: UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT

Financial news for NKTR dated on 2012-11-12: Jefferies & Company Downgrades Nektar Therapeutics from Buy to Hold, Lowers PT from \$10 to \$8

Financial news for NKTR dated on 2012-11-12: A Peek Into The Market Before The Trading Starts

Financial news for NKTR dated on 2012-11-12: AstraZeneca Announces Positive Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

Financial news for NKTR dated on 2012-11-12: Nektar To Discuss Positive Phase 3 Clinical Results For Naloxegol

Financial news for NKTR dated on 2012-11-09: Nektar Therapeutics Reports Q3 EPS \$-0.38 vs \$-0.39 Est

Financial news for NKTR dated on 2012-10-23: Option Alert: Nektar Therapeutics December 11 Call; Block Trade: 2,800 Contracts @\$1.15, Currently \$9.63

Financial news for NKTR dated on 2012-10-16: Option Alert: Nektar Therapeutics December 11/14 Call Spread; Block Trade: 10,000 Contracts @\$0.92; Currently \$10.68

Financial news for NKTR dated on 2012-10-02: Deutsche Bank Maintains Nektar Therapeutics at Buy, Raises PT from \$11 to \$13

Financial news for NKTR dated on 2012-09-27: Stocks Hitting 52-Week Highs

Financial news for NKTR dated on 2012-09-18: Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192

Financial news for NKTR dated on 2012-08-10: Jefferies & Company Maintains Nektar Therapeutics at Buy, Raises PT from \$9.50 to \$10

Financial news for NKTR dated on 2012-08-10: Citigroup Maintains Nektar Therapeutics at Buy, Raises PT from \$9 to \$11

Financial news for NKTR dated on 2012-08-09: Nektar Therapeutics Reports Q2 EPS \$-0.30 vs \$-0.34 Est; Revenues \$23.7M vs \$19.90M Est

Financial news for NKTR dated on 2012-08-07: Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol

Financial news for NKTR dated on 2012-07-24: Option Alert: Nektar Therapeutics November 11 Call; Block Trade: 2,465 Contracts @\$0.60; Currently \$9.14

Financial news for NKTR dated on 2012-07-24: Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181

Financial news for NKTR dated on 2012-06-20: Hedge Fund Manager Martin Shkreli Remains Short Nektar Therapeutics

Financial news for NKTR dated on 2012-06-07: Nektar Announces that FDA Grants Fast Track Designation to NKTR-181

Financial news for NKTR dated on 2012-06-04: Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Cash

Financial news for NKTR dated on 2012-05-25: Option Alert: Nektar Therapeutics Call Volume at 1,283% of Average; Currently \$6.87

Financial news for NKTR dated on 2012-04-02: Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192

Financial news for NKTR dated on 2012-03-28: Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

Financial news for NKTR dated on 2012-03-26: UPDATE: Hearing Nektar Therapeutics to Receive Royalties if MAP Pharmaceuticals Drug is Approved; Chatter is Drug Won't be Approved

Financial news for NKTR dated on 2012-03-26: Hearing Nektar Therapeutics to Receive Royalties if MAP Pharmaceuticals Drug is Approved

Financial news for NKTR dated on 2012-03-01: Morning Social Media Outlook for Thursday Mar 1 (CPRT, NKTR, RIMM, FNSR)

Financial news for NKTR dated on 2012-02-29: Nektar Therapeutics Reports Q4 EPS \$-0.33 vs \$-0.48 Est; Revenues \$15.8M vs \$12.66M Est

Financial news for NKTR dated on 2012-02-29: Nektar Therapeutics Up 7% After Selling Royalty Payment Agreements

Financial news for NKTR dated on 2012-02-29: Option Alert: Nektar August 8 Call; Block Trade, 5,000 Contracts

Financial news for NKTR dated on 2012-02-29: Option Alert: Nektar May 6 Call; Block Trade, 2,000 Contracts

Financial news for NKTR dated on 2012-02-29: Nektar Therapeutics Rises 11% on Royalty Deal

Financial news for NKTR dated on 2012-02-29: Nektar Therapeutics Resumes Trading

Financial news for NKTR dated on 2012-02-29: PREVIEW: Nektar Therapeutics to Resume Trading at 9am

Financial news for NKTR dated on 2012-02-29: Nektar Therapeutics Announces Agreement to Sell CIMZIA and MIRCERA Royalties to Royalty Pharma for \$124M

Financial news for NKTR dated on 2012-02-29: Nektar Therapeutics Halted, News Pending

Financial news for NKTR dated on 2012-02-01: Some stocks to watch for Thursdays session

Financial news for NKTR dated on 2012-01-20: UPDATE: Bank of America Downgrades Nektar Therapeutics to Underperform, Maintains \$6 PT

Financial news for NKTR dated on 2012-01-20: Bank of America Downgrades Nektar Therapeutics to Underperform

Financial news for NKTR dated on 2012-01-05: Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A

Financial news for NKTR dated on 2011-12-28: Notable Call Options Activity on Nektar Therapeutics

Financial news for NKTR dated on 2011-12-13: Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR-181

Financial news for NKTR dated on 2011-12-12: Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer

Financial news for NKTR dated on 2011-12-08: Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

Financial news for NKTR dated on 2011-11-29: Disclosure Insight Maintains Medium Risk Rating on Nektar Therapeutics

Financial news for NKTR dated on 2011-11-23: Nektar Therapeutics Hits 52-Week Low of \$4.10

Financial news for NKTR dated on 2011-11-21: Nektar Therapeutics Hits 52-Week Low of \$4.16

Financial news for NKTR dated on 2011-11-18: Nektar Therapeutics hits 52-Week low

Financial news for NKTR dated on 2011-11-16: NKTR hits 52-Week low

Financial news for NKTR dated on 2011-11-15: NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer

Financial news for NKTR dated on 2011-11-15: NKTR hits 52-Week Low

Financial news for NKTR dated on 2011-11-14: Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011

Financial news for NKTR dated on 2011-11-03: Nektar Therapeutics Reports Q3 EPS \$(0.21) vs \$(0.37) Est; Revenues \$27.10M vs \$15.43M Est

Financial news for NKTR dated on 2011-11-03: UPDATE: Deutsche Bank Lowers Price Target on Nektar Therapeutics to \$9

Financial news for NKTR dated on 2011-11-03: J.P. Morgan Maintains Overweight on Nektar Therapeutics

Financial news for NKTR dated on 2011-11-03: Deutsche Bank Lowers PT on Nektar Therapeutics to \$9

Financial news for NKTR dated on 2011-09-21: Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting

Financial news for NKTR dated on 2011-09-15: Too Big To Fail Party 09-15-2011

Financial news for NKTR dated on 2011-09-15: Notable Call Options Activity in Nektar Therapeutics

Financial news for NKTR dated on 2011-09-10: Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer

Financial news for NKTR dated on 2011-09-08: Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181

Financial news for NKTR dated on 2011-08-08: UPDATE: Deutsche Bank Lowers PT on Nektar Therapeutics to \$11

Financial news for NKTR dated on 2011-08-08: Deutsche Bank Lowers PT on Nektar Therapeutics to \$11

Financial news for NKTR dated on 2011-07-28: Stocks to Watch for Thursday 7/28/2011: Fresh 52 Week Highs and Lows

Financial news for NKTR dated on 2011-07-27: Stocks to Watch for Wednesday 7/27/2011: Fresh 52 Week Highs and Lows

Financial news for NKTR dated on 2011-07-20: 5 Trade Setups While Waiting For The Market To Do Something

Financial news for NKTR dated on 2011-07-18: AM Movers, Calender For The Week Ahead

Financial news for NKTR dated on 2011-06-29: Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows

Financial news for NKTR dated on 2011-06-08: J.P. Morgan Reiterates Overweight on Nektar Therapeutics

Financial news for NKTR dated on 2011-06-07: Nektar Therapeutics' NKTR-181 Achieved Long-acting Pk Profile With Analgesic Response And Excellent Safety Profile

Financial news for NKTR dated on 2011-06-02: J.P. Morgan Maintains Overweight Rating On Nektar Therapeutics

Financial news for NKTR dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for NKTR dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for NKTR dated on 2011-04-28: Deutsche Bank Maintains PT, Rating On NKTR After In-Line Results

Financial news for NKTR dated on 2011-04-28: NKTR Revenue And EPS Below Consensus But "Neither Truly Matter At This Point," Says Brean Murray

Financial news for NKTR dated on 2011-04-21: FDA Grants Orphan Drug Designation For Nektar's Investigational Drug (NKTR)

Financial news for NKTR dated on 2011-04-20: Nektar Therapeutics Receives FDA Orphan Status Approval -Rumor (NKTR)

Financial news for NKTR dated on 2011-04-20: Nektar Therapeutics Receives FDA Orphan Status Approval -Rumor (NKTR)

Financial news for NKTR dated on 2011-03-21: Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181

Financial news for NKTR dated on 2011-03-15: AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation

Financial news for NKTR dated on 2011-03-02: UPDATE: J.P. Morgan Lowers PT on Nektar Therapeutics to \$15 (NKTR)

Financial news for NKTR dated on 2011-03-02: Hapoalim Lowers PT on Nektar Therapeutics to \$17 (NKTR)

Financial news for NKTR dated on 2011-03-02: Deutsche Bank Lowers Its PT On Nektar Therapeutics To \$14 Following Earnings Report

Financial news for NKTR dated on 2011-03-02: JP Morgan Lowers PT On Nektar Therapeutics To \$15

Financial news for NKTR dated on 2011-01-20: Company News for January 20, 2011 - Corporate Summary

Financial news for NKTR dated on 2011-01-20: Company News for January 20, 2011 - Corporate Summary

Financial news for NKTR dated on 2011-01-18: Nektar Therapeutics Announces Public Offering

Financial news for NKTR dated on 2011-01-13: BROOKFIELD ASST (BAM) - Profit Tracks

Financial news for NKTR dated on 2011-01-13: BROOKFIELD ASST (BAM) - Profit Tracks

Financial news for NKTR dated on 2010-12-13: Nektar Therapeutics Falls 8.3% (NKTR)

Financial news for NKTR dated on 2010-12-13: Deutsche Bank Maintains Buy on Nektar Therapeutics

Financial news for NKTR dated on 2010-12-13: Positive Data From Nektar Therapeutics

Financial news for NKTR dated on 2010-12-13: J.P. Morgan Maintains OW Rating On Nektar Therapeutics

Financial news for NKTR dated on 2010-12-13: Benzinga's Top Pre-Market NASDAQ Losers (NKTR, PWAV, HBAN, DELL)

Financial news for NKTR dated on 2010-12-13: Nektar Therapeutics Plunging 9% In Pre-Market

Financial news for NKTR dated on 2010-11-05: Hapoalim Securities Raises Target On Nektar Therapeutics (NKTR)

Financial news for NKTR dated on 2010-11-02: Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (HSP, ELN, NKTR, ALKS)

Financial news for NKTR dated on 2010-10-14: Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (ELN, HSP, NKTR, ALKS)

Financial news for NKTR dated on 2010-06-25: Top 4 Stocks In The Drug Delivery Industry With The Highest Gross Margin (BVF, ALKS, MTXX, NKTR)

Financial news for NKTR dated on 2010-06-11: Late Day Short-Covering 06-11-2010

Financial news for NKTR dated on 2010-06-11: Market Action Listless - Watching Parade in Chicago? 06-11-2010

Financial news for NKTR dated on 2010-06-11: Calls Purchased on Nektar Therapeutics (NKTR)

Financial news for NKTR dated on 2010-06-09: Benzinga's Volume Movers (MDAS, NKTR, TCAP, EQIX)

Financial news for NKTR dated on 2010-06-08: Hapoalim Reiterates Buy Rating for Nektar Therapeutics

Financial news for NKTR dated on 2010-05-11: Benzinga's After Hours Gainers (NKTR, KBH, CAB)

Financial news for NKTR dated on 2010-04-06: Benzinga's After Hours Gainers (KEY, VANDA, NKTR)

Financial news for NKTR dated on 2010-04-06: William Blair & Co. Outlook For Nektar Therapeutics (NKTR)

Financial news for NKTR dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for NKTR dated on 2010-03-03: William Blair Maintains Nektar Therapeutics (NKTR) Outperform Rating

Financial news for NKTR dated on 2010-03-03: NKTR An Attractive Holding For The Long Term

Financial news for NKTR dated on 2010-01-14: Wednesday's Hot Stocks: Finding A Rose Among Many Thorns

Financial news for NKTR dated on 2009-09-22: New 52-Week High Stocks (GOOG, TNE, PALM, NKTR, GPS)

